Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Graft Polymer (UK) PLC ( (GB:SVNS) ) has issued an announcement.
Solvonis Therapeutics plc has appointed Professor David Nutt as Chief Scientific Officer, a move expected to enhance the company’s scientific strategy and clinical development. Professor Nutt, a leading authority in brain science and psychiatric medicine, will oversee the development of Solvonis’ expanding pipeline, including key programs targeting Alcohol Use Disorder and PTSD. His leadership is anticipated to reinforce Solvonis’ commitment to innovation in addressing urgent clinical needs, potentially impacting the company’s operations and industry positioning.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the London Stock Exchange, Solvonis is advancing a pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet needs, such as Alcohol Use Disorder and Post-Traumatic Stress Disorder.
Average Trading Volume: 14,599,829
Technical Sentiment Signal: Sell
Current Market Cap: £7.83M
Learn more about SVNS stock on TipRanks’ Stock Analysis page.